The FDA decision on the expanded use of Harmony Biosciences Holdings Inc.’s (HRMY) Wakix in the proposed indication of treating excessive daytime sleepiness or cataplexy in pediatric patients 6 years of age and older with narcolepsy is due on June 21, 2024.Wakix received FDA approval for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy in August 2019.The drug generated net product revenue of $582.0 Million for full year 2023, an increase of roughly 33%, and $154.6 million for the first quarter of 2024, an increase of 30%, year-over-year. HRMY closed Wednesday’s trading at $ 29.33, down 0.31%.